0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Galectin-3

Galectin-3

Brief Information

Name:Galectin-3
Target Synonym:Galactoside-binding protein,GALBP,Epididymis Secretory Sperm Binding Protein,MAC2,Laminin-binding protein,CBP 35,Gal-3,IgE-binding protein,Carbohydrate-binding protein 35,L-31,Lectin L-29,LGALS3,Advanced Glycation End-Product Receptor 3,Lectin, Galactosid
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GA3-H5247 Human Human Galectin-3 Protein, His Tag
GA3-H5247-structure
GA3-H5247-sds
GA3-H5129 Human Human Galectin-3 Protein, His Tag
GA3-H5129-structure
GA3-H5129-sds

Synonym Name

Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen

Background

Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ocriplasmin A-01016; THR-409 Approved Thrombogenics Jetrea, Jejetrea EU Retinal Diseases null 2012-10-17 Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Tissue Adhesions; Retinal Diseases; Stroke; Diabetic macular oedema; Eye Diseases; Symptomatic Vitreomacular Adhesion; Venous Thrombosis; Macular Degeneration; Diabetic Retinopathy Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Gal-400 Gal-400 Phase 1 Clinical Galecto Biotech Non-alcoholic Fatty Liver Disease; Liver Cirrhosis Details
TD-139 TD-139 Phase 2 Clinical The University Of Edinburgh, Lund University Foundation Idiopathic Pulmonary Fibrosis Details
Belapectin GR-MD-02 Phase 3 Clinical Galectin Therapeutics Non-alcoholic Fatty Liver Disease; Hypertension, Portal; Fibrosis; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices Details

This web search service is supported by Google Inc.

totop